Progress in Understanding Postnatal Immune Dysregulation in Allergic Disease by Susan L. Prescott et al.
INVITED REVIEW ARTICLE
Progress in Understanding Postnatal Immune Dysregulation
in Allergic Disease
Susan L. Prescott, MD, PhD, David Martino, BSc, Megan Hodder, BSc, Tara Richman, BSc,
and Meri K. Tulic, BSc, PhD
Abstract: It is increasingly unlikely that allergic disease is the result of
isolated immune defects, but rather the result of altered gene activation
patterns in intricate immune networks. This appears to be driven by
complex environmental changes, including microbial exposure, diet,
and pollutants, which are known to modify immune development in
early life, beginning in pregnancy. The first models showing possible
epigenetic mechanisms for these effects are beginning to emerge. This
review focuses on recent advances in our knowledge of the consequent
effects on postnatal immune development, highlighting recognized
differences in children with and without allergies. Although we char-
acterized essential differences in longitudinal T-cell development more
than 10 years ago, new technologies using whole genome microarrays
are now being used to examine for differential gene expression in T
cells from individuals with allergies. We have also recently performed
the first comprehensive study of the longitudinal development of innate
toll-like receptor responses in children with and without allergies during
the first 5 years of life, identifying significant differences in these
pathways as well. Finally, although there are preliminary differences in
regulatory T-cell function at birth, longitudinal studies are limited by
difficulties isolating these cells in sufficient numbers from young
children for functional studies. Thymic tissue isolated during cardiac
surgery is a rich source of regulatory T-cell function in children and
may provide further avenues for assessing differences in maturation of
these cells in individuals with allergies. To further understand the
pathogenesis of these altered patterns of immune response, future
research needs to encompass the complexity of gene-environmental
interactions, which confer individual susceptibility to environmental
exposures.
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INTRODUCTION
The modern era has been characterized by a dramatic risein susceptibility to a wide range of immune-mediated
diseases. Although the clinical manifestations of these auto-
immune and allergic conditions vary widely, the common
element to each is an underlying breakdown in immune
regulation, with failed suppression of maladaptive immune
responses directed toward either environmental or self-anti-
gens. The individual variations in disease expression are
likely to result from genetic differences in susceptibility to
the effects of environmental change. This epidemic clearly
also reflects the inherent plasticity of immune development in
response to environmental pressures, and this same plasticity
also implies opportunities for preventive intervention using
environmental modification. There is no doubt that this prob-
lem is complex and multifactorial. It is also likely that the
efficacy of prevention strategies will also vary according to
individual differences in functional genetic polymorphisms.
Thus, just as we are moving toward an era of individualized
treatment, it is equally likely that prevention strategies will
ultimately need to be individualized according to differences
in genetic susceptibility.
Before any of this can be addressed, it is essential to
have a better understanding of immune development and how
aspects of these processes fail in the development of disease
states. This will provide better insight into disease pathogen-
esis and potentially provide novel molecular targets for mod-
ifying these processes to prevent disease. It will also yield
better early markers that will allow more accurate identifica-
tion of individual susceptibility for more targeted and even-
tually more individualized interventions. Although these no-
tions are currently almost in the realms of science fiction, this
broad scope of vision is important to avoid narrowing our
concepts. The purpose of this review is to consider the current
understanding of immune development and the directions in
which this needs to evolve.
ANTENATAL EVENTS SET THE SCENE
Although the main focus here is on the postnatal de-
velopment, it is important to recognize that antenatal events
are critical in setting the stage for what happens thereafter.
Well-recognized presymptomatic differences in immune
function are present at birth in children who go on to develop
allergic disease.1This includes differences in effector T-cell
function, namely, interferon- (IFN) production, and more
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recently described differences in regulatory T-cell (Treg)
function2 and innate immune function.3 Although this may
have been previously attributed to genetically inherited pre-
disposition, there is growing recognition that this may also
reflect the first signs of environmental impact. There is now
good evidence that a number of maternal environmental
exposures in pregnancy have the capacity to modify fetal
immune development and perinatal immune function.1 The
emerging field of epigenetics also provides a new perspective
on the mechanisms by which environmental changes can be
inducing changes in gene expression and disease susceptibil-
ity in subsequent life.4 Epigenetic regulation refers to the
control of gene expression by changes in DNA and histone
methylation, histone acetylation, and chromatin structure, as
reviewed in detail elsewhere.5 These induce conformational
changes, which activate or silence genes by determining the
degree of DNA compaction and accessibility for gene tran-
scription. There are now many elegant models showing how
environmental changes at critical times during development
can profoundly alter the phenotype of genetically identical
animals, through epigenetic modification (reviewed in5,6).
Although a number of maternal exposures in pregnancy (such
as infection,7 maternal diet,8 and smoking9) are known to
modify neonatal immune function, the first models demon-
strating epigenetic mechanisms in allergic disease are now
beginning to emerge. Notably, an animal model using mater-
nal supplementation with dietary methyl donors (folate) in
pregnancy was shown to induce patterns of gene methylation
(silencing), which promoted an allergic phenotype in the
offspring, and that this effect was heritable to the next
generation.10 The significance of this is not clear in humans;
however, one recent study has reported that folate supple-
ments in pregnancy are associated with increased childhood
wheezing11 and another epidemiological study reported in-
creasing incidence of asthma in 3.5-year-old children of
mothers taking folic acid supplements during pregnancy.12
Although this clearly warrants further investigation, these
observations highlight the importance of considering antena-
tal events in subsequent patterns of immune development and
disease susceptibility.
UNDERSTANDING EARLY POSTNATAL EVENTS
In humans our opportunities to examine immune devel-
opment in detail are generally limited to peripheral blood, which
provides the context for most of our existing knowledge. How-
ever, it now seems likely that the most critical events in postnatal
immune development occur in the gastrointestinal tract, which
houses the largest reservoir of immune cells in the body. Imme-
diately after birth infants are exposed to a vast array of new
antigens, mostly from food and commensal flora, and must
quickly learn to distinguish harmless from pathogenic. As
most of these antigens are harmless, the gastrointestinal-
associated lymphoid tissue has evolved to provide strong
anti-inflammatory responses to luminal contents. Thus, “im-
mune tolerance” is the default response to oral exposures
(reviewed recently by13). Microbial colonization appears to
be essential for the establishment and homeostasis of this
tolerogenic microenvironment.14
The immunosuppressive milieu of the gut prevents
unwanted local inflammation, and also provides optimal con-
ditions for the development of highly regulated systemic
immune responses.13 Dendritic cells (DC) play a central role
in these processes. Depending on the specific patterns of
surface marker expression and cytokine production, intestinal
DC can induce a range of antigen-specific regulatory T-cell
populations including interleukin-10 (IL-10) producing Treg
(Tr1), transforming growth factor- producing Treg (Th3),
and CD4CD25FOXP3 Treg. These inhibit differentia-
tion of potential inflammatory allergen-specific effector T
cells and are essential for systemic immunosurveillance and
tolerance.
However, these tolerogenic pathways are also matched
with the capacity for DC to active inflammatory pathways,
when the inflammatory signals of an infectious threat out-
weigh tolerogenic signals. In that setting, subgroups of DC
produce IL-12 and promote IFN-producing TH1 effector T
cells to assist with pathogen clearance. Other DC subpopu-
lations can also induce TH2 differentiation under some con-
ditions. Ideally, acute effector responses are efficiently ter-
minated after an antigenic encounter, but lead to the
generation of long-lived memory T cells in preparation for
future defense. Disease states seem to arise when these
responses are directed inappropriately (toward nonpathogenic
antigens) and are ineffectively regulated. This appears to
underlie both allergic and autoimmune conditions. At this
stage the mechanisms are still poorly understood. Further
investigation into the development and regulation of toler-
ance pathways in the gastrointestinal tract remains an impor-
tant research priority.
EFFECTOR T-CELL DEVELOPMENT
Patterns of effector T-cell response have been of
central interest because their role was recognized in pro-
moting IgE production. There has been clear evidence that
most TH2 cytokines (IL-4, IL-5, IL-9, and IL-13) are
implicated in the expression and development of airways
inflammation and airway hyperactivity.15–17 Reciprocal in-
hibition between IFN-producing TH1 cells and IgE-promot-
ing “pro-allergic” TH2 lead to the earlier proposal that aller-
gic responses were the result of a “skewing” of T-cell
responses.18,19 Although this remains true to some extent, this
model has evolved to recognize a more central role for
regulatory T cells and antigen-presenting cells in dictating the
pattern of effector T-cell differentiation. Although there are
clear differences in the allergen-specific effector of individ-
uals with and without allergies, so far allergic disease cannot
be attributed to specific defects in any of these pathways. It
appears more likely that allergic disease is the result of
complex gene-environmental interactions that, under modern
environmental conditions, are enhancing the TH2 differenti-
ation at a number of developmental stages.
It is certain that TH2 genes must have been conserved
for an evolutionary advantage. Although these pathways are
important in defense from parasitic infection, they are also
crucial much earlier in development for fetal survival. During
pregnancy there is a prevailing “TH2 skew” to protect the
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fetus from maternal TH1 tissue rejection. This TH2 milieu has
a significant influence on fetal immune responses and is
reflected in the TH2 dominant responses detected in cord
blood to a range of stimuli.20 Although TH1 responses can
still be induced at this age, they are relatively immature and
there is hypermethylation (epigenetic silencing) of the IFN
gene promoter.21 Although this pattern of immune response is
adaptive in pregnancy, it is critical that this TH2 propensity is
suppressed in favor of TH1 maturation to adapt to the post-
natal environmental.22 Notably, newborns who subsequently
develop allergic disease seem to have a greater relative
immaturity of effector T-cell function, most notably in TH1
function.23,24 This had been proposed to contribute to the
persistence of TH2 propensity in children who develop aller-
gic disease.22 More recently, noted perinatal differences in
Treg function may also contribute to this.25,26 Factors that
promote TH1 maturation (and Treg maturation) such as mi-
crobial exposure are believed to be central to this process,27
and these concepts have provided additional support for the
hygiene hypothesis of allergic disease.
This model had provided a useful framework for un-
derstanding the role of T cells in the early development of
allergic disease; however, we still have not uncovered the
core pathways in pathogenesis. It is possible that this may
vary between individuals, particularly as these conditions are
so heterogeneous.
Newer approaches are using whole genome microarray
technology to examine for differential gene expression in T
cells from individuals with allergies (compared with individ-
uals without allergies). This has identified novel genes that
may be involved in the allergic response.28 We are now using
the same technology in children with food allergy to identify
patterns of early T-cell gene expression, not only during
symptomatic disease but also in the same children during the
perinatal period before disease has developed. We anticipate
that this will identify novel genes that could shed further light
on disease pathogenesis and may also provide early predic-
tors of allergic propensity.
DEVELOPMENT OF INNATE
IMMUNE FUNCTION
Antigen-presenting cells and other cells of the innate
immune system provide the first line of defense against
pathogenic environmental exposures. Among these, DC play
the most critical role in programming naive T-cell responses.
Antigen encounter in peripheral tissues induces migration and
maturation in regional nodes.29 The development of these
responses is naturally difficult to study in humans. Animal
studies suggest that resting DC stimulate TH2 immune devel-
opment unless they receive obligatory TH1-trophic signals
during antigen processing.30 These signals may occur under
conditions of infection or other local stress,31,32 which evoke
protective TH1 effector T-cell responses. Foreseeably, varia-
tions in local inflammation (such as with infection) and the
subsequent pattern of local T-cell responses could have a key
role in determining DC maturation. Animal studies confirm
that local airway DC networks are less developed in infant
animals and display markedly attenuated responses to inflam-
matory triggers.33,34 Similarly, human infants do not typically
show DC in the airways in the absence of inflammation.35
However, mature DC do appear in association with severe
respiratory infection even at this age.35 This suggests that
local tissue events in infancy can influence the maturation of
DC and modify downstream T-cell programming in early life.
Microbial products, arguably the most powerful immu-
nostimulants in the early environment, are likely to play a
particularly key role in the maturation of innate pathways,
Treg and TH1 responses, which may all act together to
prevent inappropriate allergic TH2 responses. This has logi-
cally lead to interest in possible differences in microbial
recognition pathways in infants with and without allergies,
namely, toll-like receptor (TLR) function. This family of
receptors recognizes a broad range of microbial agents36 with
different TLR signaling the presence of different microbial
components. It has been proposed that TLR-mediated activa-
tion of both APC and regulatory T cells may play an impor-
tant role in reducing the risk of TH2-mediated allergic re-
sponses (27,37 and others). Several groups have now examined
neonatal TLR responses, comparing in children with allergic
predisposition (family history) with those deemed at low risk.
Schaub et al have observed lower neonatal IFN and IL-10
responses to TLR activation.26 Although this study examined
only TLR2 responses, it is consistent with a much smaller
study that previously showed that newborns of women with
allergies (n  9) had significantly lower in vitro responses
after TLR2 ligation (with peptidoglycan) compared with
those of women without allergies (P  0.03).38 This is in
contrast to our own observations in a larger population of
infants with known allergic outcomes. Using a much wider
range of ligands (TLR2–TLR9) to assess neonatal innate
responses, we demonstrated significantly higher TLR re-
sponses at birth in relation to both maternal atopy and
subsequent infant allergic outcomes.3 The significance of
these contrasting findings still needs to be clarified. It is well
recognized that the effect of host-environmental interactions
can depend on genetic polymorphisms and that the effects of
functional TLR polymorphisms39 (and other microbial recog-
nition pathways40) vary with the level of microbial expo-
sure.39 These complex interactions may explain some of the
inconsistencies between studies performed in different envi-
ronmental contexts.41
In a separate cohort we have also performed the first
longitudinal study of these responses (to TLR2–TLR9) dur-
ing the first 5 years of life. We again observed that the group
with allergies had higher IL-10, TNF, and IL-6 TLR re-
sponses at birth compared with children without allergies. We
also observed that children who go on to develop allergic
disease have significantly higher proportion of TLR2 pDCs
at birth, compared with children who do not develop aller-
gies. Although children without allergies showed an age-
related increase in these innate responses, this was not seen in
the group with allergies and by 5 years of age children with
allergies had significantly reduced innate function compared
with control children (Tulic and Prescott, submitted for pub-
lication). This is consistent with a recent cross-sectional
comparison of TLR2 responses in 5-year-old children, which
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found that monocytes from children with allergies had im-
paired regulation of TLR2 upon peptidoglycan stimulation,
suggesting a relatively hyporesponsive state.42
Despite the increased inflammatory responses to micro-
bial responses in the early postnatal period, these children
showed persistently weaker TH1 responses to allergens with a
consistent TH2 dominance which consolidated with age.
These observations suggest that individuals with allergies
have increased inflammatory responses to microbial products
during the early perinatal period of immune programming,
but this fails to result in sufficient TH1 maturation to suppress
allergen-specific TH2 responses. This focuses attention on the
role of inflammatory cytokines, such as IL-6, in unfavourably
altering the early balance between tolerance and inflamma-




Although regulatory T cells have become a leading
focus in the development of allergic disease, they are among
the hardest cells to study. First, these cells are difficult to
identify and isolate because of the lack of specific conven-
tional surface markers, and second, their presence in such
small numbers makes it logistically difficult to perform func-
tional studies on the small volumes of blood that are available
from children. Thus, to our knowledge, there are no longitu-
dinal studies of Treg function in children with allergies versus
children without allergies.
Currently, the main developmental studies of Treg have
been with cord blood, and several have shown differences in
neonatal Treg function in relation to allergic disease.26,43
Schaub and colleagues have shown impaired neonatal Treg
function in infants at high risk of allergy.26 An earlier pre-
liminary study found that high-risk neonates had reduced
capacity to generate CD4CD25 cells after stimulation43;
however, regulatory function was not examined directly. In
our forerunner studies,2 we examined neonatal T-regulatory
function in relation to subsequent allergic outcomes (IgE-
mediated food allergy). We used the more definitive strategy
for identifying CD4CD25 CD127lo/ regulatory cells to
examine presymptomatic differences in the activity and fre-
quency of Tregs in cord blood. We observed that neonates
who developed subsequent allergy had reduced capacity to
suppress selected effector responses compared with the group
that did not develop allergies.2 Although this was not seen for
all cytokines, this provides further preliminary evidence that
allergic disease may be associated with developmental dif-
ference in these pathways.
The thymus offers a novel opportunity to document the
maturation of these pathways, which are otherwise difficult to
study in the small volumes of peripheral blood available from
young infants. Our preliminary studies show age-related
changes in the cytokine milieu in the thymus parallel changes
in peripheral immune function (Tulic, and Prescott, submitted
for publication). Specifically, the thymic microenvironment is
similarly “TH2-skewed” in the early postnatal period (with
higher IL-5 and IL-13 cytokine production), and this under-
goes age-related suppression as TH1 (IFN) production in-
creases. Thymic IL-10 responses also increase with age.
CD4CD25CD127lo/FOXP3 T regulatory (Treg) cells
are readily identified and comprise 5% of the total propor-
tion of thymocytes in neonates. This proportion increases
with age in parallel to an age-related increase in thymic
FOXP3 mRNA expression. We have examined the percent-
age of Ki67 cells as a measure of the proliferative expansion
of CD4CD25CD127lo/Treg, presumably mediated by a
combination of self- and environmental antigens. We ob-
served greater Treg expansion in the older children compared
with the younger children, suggesting that there may be
increased thymic Treg expansion with age. These data sug-
gest that the developmental changes in the thymus parallel
recognized changes in peripheral blood responses, and sup-
port our hypothesis that there are also age-related changes in
regulatory function. Similar technologies will now be used to
compare children with allergic and nonallergic phenotypes.
CONCLUSIONS
Although there has been steady progress in our under-
standing of immune development, there are still considerable
gaps in our knowledge. It is increasingly unlikely that allergic
disease is the result of isolated immune defects, but rather the
result of altered activation patterns in intricate immune net-
works. This appears to be driven by complex environmental
changes, and the diverse increase in immune dysregulation
(autoimmunity and allergy) suggests effects on common
regulatory pathways. Future research needs to encompass the
complexity of gene-environmental interactions, which confer
individual susceptibility to environmental exposures. This
complexity implies that there may be different causal path-
ways and different prevention strategies according to a mul-
titude of functional genetic polymorphisms. At this stage, this
complexity appears overwhelming, but the development of
new research methodologies, mathematical modeling and
network theory, may provide the capacity to study these
complex interactions. The current research characterizing
development pathways in more detail will be an essential
platform for these future approaches.
REFERENCES
1. Prescott SL, Clifton VL. Asthma and pregnancy: emerging evidence of
epigenetic interactions in utero. Curr Opin Allergy Clin Immunol.
2009;9(5):417–426.
2. Smith M, Tourigny MR, Noakes P, Thornton CA, Tulic MK, Prescott
SL. Children with egg allergy have evidence of reduced neonatal
CD4()CD25()CD127(lo/) regulatory T cell function. J Allergy
Clin Immunol. 2008;121:1460–1466, 1466.e1–7.
3. Prescott SL, Noakes P, Chow B, Breckler L, Thornton CA, et al.
Presymptomatic differences in toll-like receptor function in infants
who develop allergy. J Allergy Clin Immunol. 2008;122(2):391–399,
399.e1–5.
4. Martino DJ, Prescott SL. Silent mysteries: epigenetic paradigms could
hold the key to conquering the epidemic of allergy and immune disease.
Allergy. 2010;65(1):7–15.
5. Waterland RA, Michels KB. Epigenetic epidemiology of the develop-
mental origins hypothesis. Annu Rev Nutr. 2007;27:363–388.
6. Foley DL, Craig JM, Morley R, Olsson CJ, Dwyer T, et al. Prospects for
epigenetic epidemiology. Am J Epidemiol. 2009;169(4):389–400.
7. Matsuoka T, Matsubara T, Katayama K, Takeda K, Koga M, Furukawa
WAO Journal • April 2010 Postnatal Immune Dysregulation in Allergic Disease
© 2010 World Allergy Organization 165
S. Increase of cord blood cytokine-producing T cells in intrauterine
infection. Pediatr Int. 2001;43:453–457.
8. Dunstan JA, Mori TA, Barden A, Beilin LJ, Taylor AL, Holt PG,
Prescott SL. Fish oil supplementation in pregnancy modifies neonatal
allergen-specific immune responses and clinical outcomes in infants at
high risk of atopy: a randomised controlled trial. J Allergy Clin Immunol.
2003;112:1178–1184.
9. Noakes PS, Holt PG, Prescott SL. Maternal smoking in pregnancy alters
neonatal cytokine responses. Allergy. 2003;58:1053–1058.
10. Hollingsworth JW, Maruoka S, Boon K, Garantziotis S, Li Z, et al. In
utero supplementation with methyl donors enhances allergic airway
disease in mice. J Clin Invest. 2008;118:3462–3469.
11. Haberg SE, London SJ, Stigum H, Nafstad P, Nystad W. Folic acid
supplements in pregnancy and early childhood respiratory health. Arch
Dis Child. 2009;94:180–184.
12. Whitrow MJ, Moore VM, Rumbold AR, Davies MJ. Effect of supple-
mental folic acid in pregnancy on childhood asthma: a prospective birth
cohort study. Am J Epidemiol. 2009;170:1486–1493.
13. Tsuji NM, Kosaka A. Oral tolerance: intestinal homeostasis and antigen-
specific regulatory T cells. Trends Immunol. 2008;29:532–540.
14. Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. The
requirement of intestinal bacterial flora for the development of an IgE
production system fully susceptible to oral tolerance induction. J Immu-
nol. 1997;159:1739–1745.
15. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL,
Donaldson DD. Interleukin-13: central mediator of allergic asthma.
Science. 1998;282:2258–2261.
16. Temann UA, Ray P, Flavell RA. Pulmonary overexpression of IL-9
induces Th2 cytokine expression, leading to immune pathology. J Clin
Invest. 2002;109:29–39.
17. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, et al.
Direct effects of interleukin-13 on epithelial cells cause airway hyper-
reactivity and mucus overproduction in asthma. Nat Med. 2002;8:885–
889.
18. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion pat-
terns and functions of helper T cells. Adv Immunol. 1989;46:111–147.
19. Romagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol
Today. 1991;12:256–257.
20. Prescott S, Macaubas C, Holt BJ, Smallacombe TB, Loh R, Sly PD, Holt
PG. Transplacental priming of the human immune system to environ-
mental allergens: universal skewing of initial T-cell responses towards
Th-2 cytokine profile. J Immunol. 1998;160:4730–4737.
21. White GP, Watt PM, Holt BJ, Holt PG. Differential patterns of meth-
ylation of the IFN-gamma promoter at CpG and non-CpG sites underlie
differences in IFN-gamma gene expression between human neonatal and
adult CD45RO- T cells. J Immunol. 2002;168:2820–2827.
22. Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD. Develop-
ment of allergen-specific T-cell memory in atopic and normal children.
Lancet. 1999;353(9148):196–200.
23. Tang MLK, Kemp AS, Thorburn J, Hill D. Reduced interferon gamma
secretion in neonates and subsequent atopy. Lancet. 1994;344:983–985.
24. Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Loh R, Holt
PG. Reciprocal age-related patterns of allergen-specific T-cell immunity
in normal vs. atopic infants. Clin Exp Allergy. 1998;28 Suppl 5:39–44;
discussion 50–1.
25. Smith M, Tourigney MR, Noakes P, Thornton CA, Tulic MK,
Prescott SL. Egg allergic children have evidence of reduced neonatal
CD4CD25CD127 lo/ T regulatory cell function. J Allergy Clin
Immunol. 2008;121(6):1460–1466.
26. Schaub B, Liu J, Ho¨ppler S, Haug S, Sattler C, et al. Impairment of
T-regulatory cells in cord blood of atopic mothers. J Allergy Clin
Immunol. 2008;121:1491–1499, 1499.e1–13.
27. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic
disease: revisiting the hygiene hypothesis. Nat Rev Immunol. 2001;1:
69–75.
28. Bosco A, McKenna KL, Devitt CJ, Firth MJ, Sly PD, Holt PG.
Identification of novel Th2-associated genes in T memory responses to
allergens. J Immunol. 2006;176:4766–4777.
29. Huh JC, Strickland DH, Jahnsen FL, Turner DJ, Thomas JA, et al.
Bidirectional interactions between antigen-bearing respiratory tract den-
dritic cells (DCs) and T cells precede the late phase reaction in exper-
imental asthma: DC activation occurs in the airway mucosa but not in
the lung parenchyma. J Exp Med. 2003;198:19–30.
30. Stumbles PA, Thomas JA, Pimm CL, Lee PT, Venaille TJ, Proksch S,
Holt PG. Resting respiratory tract dendritic cells preferentially stimulate
T helper cell type 2 (Th2) responses and require obligatory cytokine
signals for induction of Th1 immunity. J Exp Med. 1998;188:2019–
2031.
31. Sta¨mpfli MR, Wiley RE, Neigh GS, Gajewska BU, Lei XF, et al.
GM-CSF transgene expression in the airway allows aerosolized ovalbu-
min to induce allergic sensitization in mice. J Clin Invest. 1998;102:
1704–1714.
32. Yamamoto N, Suzuki S, Shirai A, Suzuki M, Nakazawa M, Nagashima
Y, Okubo T. Dendritic cells are associated with augmentation of antigen
sensitization by influenza A virus infection in mice. Eur J Immunol.
2000;30:316–326.
33. Nelson DJ, McMenamin C, McWilliam AS, Brenan M, Holt PG.
Development of the airway intraepithelial dendritic cell network in the
rat from class II MHC (Ia) negative precursors: differential regulation of
Ia expression at different levels of the respiratory tract. J Exp Med.
1994;179:203–212.
34. Nelson DJ, Holt PG. Defective regional immunity in the respiratory tract
of neonates is attributable to hyporesponsiveness of local dendritic cells
to activation signals. J Immunol. 1995;155:3517–3524.
35. Tschernig T, Debertin AS, Paulsen F, Kleemann WJ, Pabst R. Dendritic
cells in the mucosa of the human trachea are not regularly found in the
first year of life. Thorax. 2001;56:427–431.
36. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate
immune response. Nature. 2000;406:782–787.
37. Holt PG, Macaubas C, Prescott SL, Sly PD. Microbial stimulation as an
aetiologic factor in atopic disease. Allergy. 1999;54 Suppl 49:12–16.
38. Amoudruz P, Holmlund U, Malmstro¨m V, Trollmo C, Bremme K,
Scheynius A, Sverremark-Ekstro¨m E. Neonatal immune responses to
microbial stimuli: is there an influence of maternal allergy? J Allergy
Clin Immunol. 2005;115:1304–1310.
39. Eder W, Klimecki W, Yu L, von Mutius E, Riedler J, et al. Toll-like
receptor 2 as a major gene for asthma in children of European farmers.
J Allergy Clin Immunol. 2004;113:482–488.
40. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez
FD. A polymorphism in the 5 flanking region of the CD14 gene is
associated with circulating soluble CD14 levels and with total serum
immunoglobulin E. Am J Respir Cell Mol Biol. 1999;20:976–983.
41. Vercelli D. Genetic polymorphism in allergy and asthma. Curr Opin
Immunol. 2003;15:609–613.
42. Amoudruz P, Holmlund U, Saghafian-Hedengren S, Nilsson C, Sverre-
mark-Ekstro¨m E. Impaired toll-like receptor 2 signalling in monocytes
from 5-year-old allergic children. Clin Exp Immunol. 2009;155:387–
394.
43. Haddeland U, Karstensen AB, Farkas L, Bo KO, Pirhonen J, et al.
Putative regulatory T cells are impaired in cord blood from neonates
with hereditary allergy risk. Pediatr Allergy Immunol. 2005;16:104–
112.
Prescott et al WAO Journal • April 2010
© 2010 World Allergy Organization166
